Research Topics
| Daniel CourielSummaryAffiliation: The University of Texas Country: USA Publications
| Collaborators
|
Detail Information
Publications
An unusual cause of alveolar hemorrhage post hematopoietic stem cell transplantation: a case reportSachin Gupta
Department of Pulmonary Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
BMC Cancer 6:87. 2006..Diffuse alveolar hemorrhage associated with Strongyloides stercoralis hyperinfection in stem cell transplant patients has been rarely reported...
Tumor necrosis factor-alpha blockade for the treatment of acute GVHDDaniel Couriel
Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 104:649-54. 2004..Survival after steroid-resistant acute GVHD continues to be problematic. The possibility of excessive fungal and other infections must be explored further...- Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantationDaniel R Couriel
Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
Biol Blood Marrow Transplant 10:178-85. 2004..It is interesting to note that nonrelapse mortality with nonmyeloablative regimens in older and more debilitated patients was low (14%) and comparable to that achieved with standard high-dose regimens in younger patients... - Acute graft-versus-host disease: pathophysiology, clinical manifestations, and managementDaniel Couriel
Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
Cancer 101:1936-46. 2004..In this review, the authors summarize the most current knowledge on the pathophysiology, clinical manifestations, and management of this potentially life-threatening transplantation complication... - Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Daniel Couriel
University of Texas MD Anderson Cancer Center, Houston, 77030, USA
Biol Blood Marrow Transplant 12:375-96. 2006..Optimal care of patients with chronic GVHD often requires a multidisciplinary approach... - Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHDDaniel R Couriel
Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 423, Houston, TX 77030, USA
Blood 107:3074-80. 2006..Objective responses were observed in a substantial number of patients with both skin and visceral chronic GVHD failing corticosteroids and other immunosuppression... 
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDSBorje S Andersson
Department of Stem Cell Transplantation and Cellular Therapy, U T M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030 4009, USA
Biol Blood Marrow Transplant 14:672-84. 2008..These results support replacing BuCy +/- ATG with Bu-Flu +/- rabbit-antithymocyte globulin (ATG), and warrant a prospective comparison between allogeneic HSCT and conventional induction/consolidation chemotherapy for AML in CR1...- Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemiaPartow Kebriaei
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Blood 110:3456-62. 2007..TRM rates are acceptable in this high-risk population but increase over time... - Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximabIssa F Khouri
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
Blood 111:5530-6. 2008..Only 5 patients were still undergoing immunosuppressive therapy at the time of last follow-up. We believe that the described results are a step forward toward developing a curative strategy for recurrent follicular lymphoma... - Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSMarcos de Lima
Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, Houston, TX 77030, USA
Blood 104:857-64. 2004..The results suggest that intravenous busulfan-fludarabine is an efficacious, reduced-toxicity, myeloablative-conditioning regimen for patients with AML or MDS undergoing HSCT... - Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemiasMarcos de Lima
Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
Cancer 97:1242-7. 2003..Decitabine is a hypomethylating agent that has activity in patients with leukemia. The authors combined decitabine with busulfan and cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation... - Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalanBetul Oran
M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Biol Blood Marrow Transplant 13:454-62. 2007..Use of unrelated donors increased the risk of NRM only among patients with active disease. FM and HSCT elicited long-term disease control in a significant fraction of this high-risk cohort... - Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized studySimrit Parmar
Department of Stem Cell Transplantation and Cell Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA
J Clin Oncol 29:294-302. 2011.... - Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myelomaMuzaffar H Qazilbash
Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 106:1084-9. 2006..The outcomes of salvage autologous or allogeneic transplants were analyzed retrospectively in patients relapsing after an autograft... - Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantationMarcos de Lima
Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 104:865-72. 2004..Survival was improved for patients in CR at transplantation. In conclusion, FM provided better disease control though at a cost of increased TRM and morbidity... - Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type mattersMaha El-Zimaity
Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA
Blood 103:4674-80. 2004..We concluded that HC is more prevalent in MUD and UCB transplantations... - Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing scheduleTimothy Madden
Pharmaceutical Development Center, The University of Texas MD Anderson Cancer Center, Houston, Texas 770554, USA
Biol Blood Marrow Transplant 13:56-64. 2007..8 mg/kg) to 130 mg/m2 (approximately 3.2 mg/kg). Further, once-daily intravenous busulfan dosing is convenient, favoring its more widespread application... - Treatment of relapsing refractory diffuse large cell lymphoma after matched unrelated donor bone marrow transplant with immunosuppression withdrawal and rituximabRaymond Wong
Department of Blood and Marrow Transplantation, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030-4009, USA
Leuk Lymphoma 44:829-32. 2003..Lymphoma relapse occurred 4 months post-transplant. Immunosuppression withdrawal plus rituximab induced a complete response. He remains in complete remission (CR) 11 months post-immunosuppression withdrawal and 15 months post-transplant... - Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplantQaiser Bashir
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D AndersonCancer Center, Houston, TX, USA
Leuk Lymphoma 53:915-9. 2012..ATG levels were not associated with clinical outcomes. Thus, our results favor the use of ATG 4.5 mg/kg over ATG 7.5 mg/kg in patients undergoing unrelated donor hematopoietic cell transplant with reduced-intensity conditioning regimens... - Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantationRaymond Wong
Department of Blood and Marrow Transplantation, University of Texas M.D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Biol Blood Marrow Transplant 11:108-14. 2005.... - Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomasIssa F Khouri
Department of Blood and Marrow Transplantation, Unit 423, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 23:2240-7. 2005.... - Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?Daniel Couriel
Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 12:37-40. 2006..All of these results indicate activity of extracorporeal photopheresis in acute and chronic GVHD, which warrants further evaluation of this therapy in well-designed, prospective, controlled studies... - Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survivalIssa F Khouri
Department of Blood and Marrow Transplantation, M D Anderson Cancer Center, Houston, Tex 77030, USA
Exp Hematol 32:28-35. 2004..To investigate the graft-vs-leukemia effect of allogeneic stem cell transplantation after a nonablative conditioning regimen as treatment for patients with chronic lymphocytic leukemia... - Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemiaMuzaffar H Qazilbash
Department of Blood and Marrow Transplantation, UT MD Anderson Cancer Center, Houston, 77030, USA
Am J Hematol 80:43-5. 2005..The patient developed autoimmune hemolytic anemia that failed to respond to steroids, intravenous immunoglobulins, and plasma exchange. She was then treated with rituximab that resulted in fatal acute liver toxicity... - Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemiaBorje S Andersson
Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston 77005, USA
Biol Blood Marrow Transplant 8:477-85. 2002..Given the ability of i.v. Bu to provide a more consistent per-dose AUC, these results should be useful in designing future i.v.V Bu-based treatment protocols for stem cell transplantation... - CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humansMarta Stanzani
Transplant Immunology Laboratory, MD Anderson Cancer Center, SCRB 3.3019, 7455 Fannin St, Houston, TX 77030, USA
Blood 103:1140-6. 2004.... - Graft-versus-host disease after allogeneic stem cell transplantation: evolving concepts and novel therapies including photopheresisKrishna V Komanduri
Transplant Immunology Section, Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 12:1-6. 2006.... - Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantationRaymond Wong
Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
Br J Haematol 122:128-34. 2003..One patient was changed to cyclosporine. In most patients, subsequent treatment with tacrolimus was well tolerated without recurrence of neurotoxicity... - Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood unitsMarcos de Lima
Department of Blood and Marrow Transplantation, Pathology, and Leukaemia, M D Anderson Cancer Center, Houston, TX 77030, USA
Br J Haematol 119:773-6. 2002..Triple chimaerism was present from relapse until death due to leukaemia. This approach may potentially improve UCB transplantation outcome for adults lacking a histocompatible donor... - Endoscopic biopsy diagnosis of acute gastrointestinal graft-versus-host disease: rectosigmoid biopsies are more sensitive than upper gastrointestinal biopsiesWilliam A Ross
Department of Gastroenterology, Hepatology and Nutrition, The University of Texas M D Anderson Cancer Center, Houston, Texas 77380, USA
Am J Gastroenterol 103:982-9. 2008..The portion of the GI tract with the highest diagnostic yield is a topic of debate. Our aim was to evaluate the sensitivity of simultaneous biopsy of the stomach, duodenum, and rectosigmoid in establishing the diagnosis of GI GVHD... - Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experiencePaolo Anderlini
The U T M D Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030 USA
Haematologica 93:257-64. 2008..We here present an update of our single-center experience with fludarabine-melphalan as a preparative regimen... - Colonic graft-versus-host diseaseWilliam A Ross
Department of Gastrointestinal Medicine and Nutrition, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Curr Opin Gastroenterol 21:64-9. 2005..Gastrointestinal GVHD frequently involves the colon and complicates management of these seriously ill patients. This review updates the diagnosis and management of colonic GVHD... - A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host diseaseMargaret L Macmillan
Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
Blood 109:2657-62. 2007..This prospective, multicenter, randomized clinical trial for steroid-resistant acute GVHD serves as a model for future evaluation of new agents... - Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group ReportKirk R Schultz
British Columbia Children s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
Biol Blood Marrow Transplant 12:126-37. 2006..Both approaches have merit and should be pursued. The consistent treatment and standardized documentation needed to support biomarker studies are most likely to be satisfied in prospective clinical trials... - Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group reportSteven Z Pavletic
National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1203, USA
Biol Blood Marrow Transplant 12:252-66. 2006..The proposed response criteria are based on current expert consensus opinion and are intended to improve consistency in the conduct and reporting of chronic GVHD trials, but their use remains to be demonstrated in practice... - A survey of diagnosis, management, and grading of chronic GVHDStephanie J Lee
Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Biol Blood Marrow Transplant 8:32-9. 2002..We conclude that studies defining appropriate diagnostic pathways, criteria for disease activity, and prognosis could help standardize management of cGVHD. There is an urgent need to develop and test new approaches to treat cGVHD... - Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefitBorje S Andersson
Biol Blood Marrow Transplant 9:722-4. 2003 - Transplantation's greatest challenges: advances in chronic graft-versus-host diseaseWarren D Shlomchik
Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA
Biol Blood Marrow Transplant 13:2-10. 2007..In this overview, we address 3 key areas related to chronic GVHD that hold the highest promise for major advances in the near future: pathobiology, response criteria, and therapy... - National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group reportPaul J Martin
Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington 98109 1024, USA, and Hopital St Louis, Paris, France
Biol Blood Marrow Transplant 12:491-505. 2006..The use of consistent standards in clinical trial designs to evaluate agents that have activity in pathogenic pathways could facilitate advances in the treatment of chronic GVHD... - National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group reportAlexandra H Filipovich
Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229, USA
Biol Blood Marrow Transplant 11:945-56. 2005..It is currently recommended that systemic therapy be considered for patients who meet criteria for chronic GVHD of moderate to severe global severity... - The graft-versus-leukemia effect in leukemia cutisRaymond Wong
Transplantation 76:619-20. 2003 - Bilateral marginal keratitis associated with engraftment syndrome after hematopoietic stem cell transplantationEric Dai
Department of Ophthalmology, The University of Texas Medical Branch, Galveston, TX, USA
Cornea 26:756-8. 2007..To report the first case of bilateral marginal keratitis in the setting of engraftment syndrome in a patient who had undergone hematopoietic stem cell transplantation...